The Regional Biocontainment Laboratory (RBL) at Duke was built with funding from NIH to support basic research to develop drugs, diagnostics, and vaccines for emerging and reemerging infections and biodefense. The RBL has a comprehensive safety and operations program to provide state-of-the-art biocontainment facilities for BSL2 and BSL3 research. The RBL was fully-commissioned in late 2007 (NIAID UC6-AI058607).
The Duke RBL supports basic research programs and has three collaborative core units that focus on Immunology, Virology, and Microbiology. These units are available to Duke faculty and their collaborators as fee-for-service shared resources. Through any of these units, users can receive safety/security training, animal model support and use of the containment environment. These units can be utilized separately or all together to provide comprehensive study support (regulatory compliance, study design, study execution and data analysis).
The Duke Regional Biocontainment Laboratory supports a comprehensive sponsored research portfolio with a focus on Vaccine and Therapeutic Development. Excess research support capacity in the RBL is also available to investigators as cost recovery through the three collaborative shared resource units.
The Duke RBL supports sponsored research programs in the areas of:
Gregory Sempowski, Ph.D., RBL Director
Heather Lynch,Ph.D, Assistant Director for RBL Program Management and Development